Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,286.00
(
0.64%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.03
(
-0.62%
)
Bitcoin
74,080.72
(
0.18%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 94013

Tuesday, 10/19/2010 7:45:57 PM

Tuesday, October 19, 2010 7:45:57 PM

Post# of 257253
Data from GILD’s two phase-3 trials of Quad* vs Atripla and Quad vs Truvada+Reyataz will be available in 3Q11 and 4Q11, respectively, according to GILD’s 3Q10 CC today.

*Quad is a 4-drug combination pill consisting of Viread, Emtriva, Elvitegravir, and Cobicistat (GILD’s proprietary PK-boosting agent).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up